Global Leukocyte Adhesion Deficiency Therapeutics Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Leukocyte Adhesion Deficiency Therapeutics market size was valued at US$ 9684 million in 2024 and is forecast to a readjusted size of USD 18670 million by 2031 with a CAGR of 10.0% during review period.
Leukocyte Adhesion Deficiency (LAD) is a rare primary immunodeficiency disorder characterized by defects in leukocyte adhesion molecules, impairing the ability of white blood cells to migrate to sites of infection. Management of LAD involves a multifaceted approach, including early diagnosis, aggressive treatment of infections, and prophylactic antibiotic therapy to prevent recurrent bacterial infections. In severe cases, hematopoietic stem cell transplantation (HSCT) remains the only curative option and is often recommended for long-term survival. Emerging therapies such as gene therapy are also under investigation, particularly for specific subtypes of LAD. The overall goal of management is to improve immune function, reduce infection frequency, and enhance the patient's quality of life through timely and individualized treatment strategies.
This report is a detailed and comprehensive analysis for global Leukocyte Adhesion Deficiency Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Leukocyte Adhesion Deficiency Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031
Global Leukocyte Adhesion Deficiency Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Leukocyte Adhesion Deficiency Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Leukocyte Adhesion Deficiency Therapeutics market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Leukocyte Adhesion Deficiency Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Leukocyte Adhesion Deficiency Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Rocket Pharmaceuticals, Orchard Therapeutics, Avrobio, Inc., Magenta Therapeutics, Lonza Group, Bluebird Bio, Be The Match BioTherapies, CSL Behring, Gilead Sciences, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Leukocyte Adhesion Deficiency Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Stem Cell Therapies
Surgery Transplantation
Other
Market segment by Application
Hospital
Research Institution
Other
Market segment by players, this report covers
Rocket Pharmaceuticals
Orchard Therapeutics
Avrobio, Inc.
Magenta Therapeutics
Lonza Group
Bluebird Bio
Be The Match BioTherapies
CSL Behring
Gilead Sciences
Novartis
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Leukocyte Adhesion Deficiency Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Leukocyte Adhesion Deficiency Therapeutics, with revenue, gross margin, and global market share of Leukocyte Adhesion Deficiency Therapeutics from 2020 to 2025.
Chapter 3, the Leukocyte Adhesion Deficiency Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Leukocyte Adhesion Deficiency Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Leukocyte Adhesion Deficiency Therapeutics.
Chapter 13, to describe Leukocyte Adhesion Deficiency Therapeutics research findings and conclusion.
Leukocyte Adhesion Deficiency (LAD) is a rare primary immunodeficiency disorder characterized by defects in leukocyte adhesion molecules, impairing the ability of white blood cells to migrate to sites of infection. Management of LAD involves a multifaceted approach, including early diagnosis, aggressive treatment of infections, and prophylactic antibiotic therapy to prevent recurrent bacterial infections. In severe cases, hematopoietic stem cell transplantation (HSCT) remains the only curative option and is often recommended for long-term survival. Emerging therapies such as gene therapy are also under investigation, particularly for specific subtypes of LAD. The overall goal of management is to improve immune function, reduce infection frequency, and enhance the patient's quality of life through timely and individualized treatment strategies.
This report is a detailed and comprehensive analysis for global Leukocyte Adhesion Deficiency Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Leukocyte Adhesion Deficiency Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031
Global Leukocyte Adhesion Deficiency Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Leukocyte Adhesion Deficiency Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Leukocyte Adhesion Deficiency Therapeutics market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Leukocyte Adhesion Deficiency Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Leukocyte Adhesion Deficiency Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Rocket Pharmaceuticals, Orchard Therapeutics, Avrobio, Inc., Magenta Therapeutics, Lonza Group, Bluebird Bio, Be The Match BioTherapies, CSL Behring, Gilead Sciences, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Leukocyte Adhesion Deficiency Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Stem Cell Therapies
Surgery Transplantation
Other
Market segment by Application
Hospital
Research Institution
Other
Market segment by players, this report covers
Rocket Pharmaceuticals
Orchard Therapeutics
Avrobio, Inc.
Magenta Therapeutics
Lonza Group
Bluebird Bio
Be The Match BioTherapies
CSL Behring
Gilead Sciences
Novartis
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Leukocyte Adhesion Deficiency Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Leukocyte Adhesion Deficiency Therapeutics, with revenue, gross margin, and global market share of Leukocyte Adhesion Deficiency Therapeutics from 2020 to 2025.
Chapter 3, the Leukocyte Adhesion Deficiency Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Leukocyte Adhesion Deficiency Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Leukocyte Adhesion Deficiency Therapeutics.
Chapter 13, to describe Leukocyte Adhesion Deficiency Therapeutics research findings and conclusion.
Table of Contents
85 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
